Current trends in the management of Richter's syndrome

por Allan, John N, Furman, Richard R
Publicado 2019

CD39 activity correlates with stage and inhibits platelet reactivity in chronic lymphocytic leukemia

por Pulte, Dianne, Olson, Kim E, Broekman, M Johan, Islam, Naziba, Ballard, Harold S, Furman, Richard R, Olson, Ashley E, Marcus, Aaron J
Publicado 2007

Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice

por O’Brien, Susan M., Brown, Jennifer R., Byrd, John C., Furman, Richard R., Ghia, Paolo, Sharman, Jeff P., Wierda, William G.
Publicado 2021

Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients

por Pera, Benet, Tang, Tiffany, Marullo, Rossella, Yang, Shao-Ning, Ahn, Haelee, Patel, Jayeshkumar, Elstrom, Rebecca, Ruan, Jia, Furman, Richard, Leonard, John, Cerchietti, Leandro, Martin, Peter
Publicado 2016

Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial

por Ghia, Paolo, Coutre, Steven E., Cheson, Bruce D., Barrientos, Jacqueline C., Hillmen, Peter, Pettitt, Andrew R., Zelenetz, Andrew D., Shreay, Sanatan, Hallek, Michael, Furman, Richard R.
Publicado 2020

Targeting metabolism and survival in chronic lymphocytic leukemia and Richter syndrome cells by a novel NF-κB inhibitor

por Vaisitti, Tiziana, Gaudino, Federica, Ouk, Samedy, Moscvin, Maria, Vitale, Nicoletta, Serra, Sara, Arruga, Francesca, Zakrzewski, Johannes L., Liou, Hsiou-Chi, Allan, John N., Furman, Richard R., Deaglio, Silvia
Publicado 2017

Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma

por Yamshon, Samuel, Chen, Gui Zhen, Gribbin, Caitlin, Christos, Paul, Shah, Bijal, Schuster, Stephen J., Smith, Sonali M., Svoboda, Jakub, Furman, Richard R., Leonard, John P., Martin, Peter, Ruan, Jia
Publicado 2023

Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B‐cell receptor pathway inhibitor

por Wierda, William G., Byrd, John C., Davids, Matthew S., Furman, Richard R., Cheson, Bruce D., Barr, Paul M., Eradat, Herbert, Heffner, Leonard, Zhou, Lang, Verdugo, Maria, Potluri, Jalaja, Choi, Michael
Publicado 2018

P1200: ZILOVERTAMAB VEDOTIN (MK-2140) IN RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): UPDATED RESULTS FROM THE PHASE 1 WAVELINE-001 STUDY

por Spurgeon, Stephen, Mei, Matthew, Barr, Paul M., Barrientos, Jacqueline, de Vos, Sven, Furman, Richard, Patel, Krish, Thompson, Philip, Choi, Michael Y., Kallam, Avyakta, Wang, Siruo, Ogbu, Uzor, Marinello, Patricia, Wang, Michael
Publicado 2023

A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors

por de Vos, Sven, Forero-Torres, Andres, Ansell, Stephen M, Kahl, Brad, Cheson, Bruce D, Bartlett, Nancy L, Furman, Richard R, Winter, Jane N, Kaplan, Henry, Timmerman, John, Whiting, Nancy C, Drachman, Jonathan G, Advani, Ranjana
Publicado 2014

The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab

por Kreuzer, Karl-Anton, Furman, Richard R., Stilgenbauer, Stephan, Dubowy, Ronald L., Kim, Yeonhee, Munugalavadla, Veerendra, Lilienweiss, Esther, Reinhardt, Hans Christian, Cramer, Paula, Eichhorst, Barbara, Hillmen, Peter, O’Brien, Susan M., Pettitt, Andrew R., Hallek, Michael
Publicado 2019

The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy

por Arruga, Francesca, Rubin, Marta, Papazoglou, Despoina, Iannello, Andrea, Ioannou, Nikolaos, Moia, Riccardo, Rossi, Davide, Gaidano, Gianluca, Coscia, Marta, Laurenti, Luca, D’Arena, Giovanni, Allan, John N., Furman, Richard R., Vaisitti, Tiziana, Ramsay, Alan G., Deaglio, Silvia
Publicado 2023

Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients

por Brown, Jennifer R., Byrd, John C., Ghia, Paolo, Sharman, Jeff P., Hillmen, Peter, Stephens, Deborah M., Sun, Clare, Jurczak, Wojciech, Pagel, John M., Ferrajoli, Alessandra, Patel, Priti, Tao, Lin, Kuptsova-Clarkson, Nataliya, Moslehi, Javid, Furman, Richard R.
Publicado 2021

Management of adverse events associated with idelalisib treatment: expert panel opinion

por Coutré, Steven E., Barrientos, Jacqueline C., Brown, Jennifer R., de Vos, Sven, Furman, Richard R., Keating, Michael J., Li, Daniel, O’Brien, Susan M., Pagel, John M., Poleski, Martin H., Sharman, Jeff P., Yao, Nai-Shun, Zelenetz, Andrew D.
Publicado 2015

Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

por Coutre, Steven E., Flinn, Ian W., de Vos, Sven, Barrientos, Jacqueline C., Schreeder, Marshall T., Wagner-Johnson, Nina D., Sharman, Jeff P., Boyd, Thomas E., Fowler, Nathan, Dreiling, Lyndah, Kim, Yeonhee, Mitra, Siddhartha, Rai, Kanti, Leonard, John P., Furman, Richard R.
Publicado 2018

Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy

por Mato, Anthony R., Wierda, William G., Davids, Matthew S., Cheson, Bruce D., Coutre, Steven E., Choi, Michael, Furman, Richard R., Heffner, Leonard, Barr, Paul M., Eradat, Herbert, Ford, Sharanya M., Zhou, Lang, Verdugo, Maria, Humerickhouse, Rod A., Potluri, Jalaja, Byrd, John C.
Publicado 2019

Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton‐Pump Inhibitors

por Sharma, Shringi, Pepin, Xavier, Burri, Harini, Zheng, Lianqing, Kuptsova‐Clarkson, Nataliya, de Jong, Anouk, Yu, Ting, MacArthur, Holly L., Majewski, Michal, Byrd, John C., Furman, Richard R., Ware, Joseph A., Mann, James, Ramies, David, Munugalavadla, Veerendra, Sheridan, Louise, Tomkinson, Helen
Publicado 2022

Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies

por Licht, Christoph, Greenbaum, Larry A, Muus, Petra, Babu, Sunil, Bedrosian, Camille L, Cohen, David J, Delmas, Yahsou, Douglas, Kenneth, Furman, Richard R, Gaber, Osama A, Goodship, Timothy, Herthelius, Maria, Hourmant, Maryvonne, Legendre, Christophe M, Remuzzi, Giuseppe, Sheerin, Neil, Trivelli, Antonella, Loirat, Chantal
Publicado 2015

Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single‐agent ibrutinib

por Jones, Jeffrey A., Hillmen, Peter, Coutre, Steven, Tam, Constantine, Furman, Richard R., Barr, Paul M., Schuster, Stephen J., Kipps, Thomas J., Flinn, Ian W., Jaeger, Ulrich, Burger, Jan A., Cheng, Mei, Ninomoto, Joi, James, Danelle F., Byrd, John C., O'Brien, Susan M.
Publicado 2017

Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials

por Jones, Jeffrey, Mato, Anthony, Coutre, Steven, Byrd, John C., Furman, Richard R., Hillmen, Peter, Osterborg, Anders, Tam, Constantine, Stilgenbauer, Stephan, Wierda, William G., Heerema, Nyla A., Eckert, Karl, Clow, Fong, Zhou, Cathy, Chu, Alvina D., James, Danelle F., O'Brien, Susan M.
Publicado 2018